List of bibliographic references
Number of relevant bibliographic references: 8.
| Ident. | Authors (with country if any) | Title |
|---|
| 000A44 (2016) |
Bernhard Reis [Suisse] ; Lori Jukofsky [États-Unis] ; Gong Chen [États-Unis] ; Giovanni Martinelli [Italie] ; Hua Zhong [États-Unis] ; W. Venus So [États-Unis] ; Michael J. Dickinson [Australie] ; Mark Drummond [Royaume-Uni] ; Sarit Assouline [Canada] ; Maneja Hashemyan [États-Unis] ; Michel Theron [Suisse] ; Steven Blotner [États-Unis] ; Je-Hwan Lee [Corée du Sud] ; Margaret Kasner [États-Unis] ; Sung-Soo Yoon [Corée du Sud] ; Ruediger Rueger [Allemagne] ; Karen Seiter [États-Unis] ; Steven A. Middleton [États-Unis] ; Kevin R. Kelly [États-Unis] ; Norbert Vey [France] ; Karen Yee [Canada] ; Gwen Nichols [États-Unis] ; Lin-Chi Chen [États-Unis] ; William E. Pierceall [États-Unis] | Acute myeloid leukemia patients’ clinical response to idasanutlin (RG7388) is associated with pre-treatment MDM2 protein expression in leukemic blasts |
| 000C48 (2015) |
Hervé Dombret [France] ; John F. Seymour [Australie] ; Aleksandra Butrym [Pologne] ; Agnieszka Wierzbowska [Pologne] ; Dominik Selleslag [Belgique] ; Jun Ho Jang [Corée du Sud] ; Rajat Kumar [Canada] ; James Cavenagh [Royaume-Uni] ; Andre C. Schuh [Canada] ; Anna Candoni [Italie] ; Christian Récher [France] ; Irwindeep Sandhu [Canada] ; Teresa Bernal Del Castillo [Espagne] ; Haifa Kathrin Al-Ali [Allemagne] ; Giovanni Martinelli [Italie] ; Jose Falantes [Espagne] ; Richard Noppeney [Allemagne] ; Richard M. Stone [États-Unis] ; Mark D. Minden [Canada] ; Heidi Mcintyre [États-Unis] ; Steve Songer [États-Unis] ; Lela M. Lucy [États-Unis] ; C. L. Beach [États-Unis] ; Hartmut Döhner [Allemagne] | International phase 3 study of azacitidine vs conventional care regimens in older patients with newly diagnosed AML with >30% blasts |
| 000F88 (2014) |
Simona Soverini [Italie] ; Susan Branford [Australie] ; Franck E. Nicolini [France] ; Moshe Talpaz [États-Unis] ; Michael W N. Deininger [États-Unis] ; Giovanni Martinelli [Italie] ; Martin C. Müller [Allemagne] ; Jerald P. Radich [États-Unis] ; Neil P. Shah [États-Unis] | Implications of BCR-ABL1 kinase domain-mediated resistance in chronic myeloid leukemia. |
| 001082 (2014) |
Hagop M. Kantarjian [États-Unis] ; Jorge E. Cortes [États-Unis] ; Dong-Wook Kim [Corée du Sud] ; H. Jean Khoury [États-Unis] ; Tim H. Brümmendorf [Allemagne] ; Kimmo Porkka [Finlande] ; Giovanni Martinelli [Italie] ; Simon Durrant [Australie] ; Eric Leip ; Virginia Kelly ; Kathleen Turnbull [États-Unis] ; Nadine Besson [France] ; Carlo Gambacorti-Passerini [Italie] | Bosutinib safety and management of toxicity in leukemia patients with resistance or intolerance to imatinib and other tyrosine kinase inhibitors |
| 001337 (2013) |
Michele Baccarani [Italie] ; Michael W. Deininger [États-Unis] ; Gianantonio Rosti [Italie] ; Andreas Hochhaus [Allemagne] ; Simona Soverini [Italie] ; Jane F. Apperley [Royaume-Uni] ; Francisco Cervantes [Espagne] ; Richard E. Clark [Royaume-Uni] ; Jorge E. Cortes [États-Unis] ; François Guilhot [France] ; Henrik Hjorth-Hansen [Norvège] ; Timothy P. Hughes [Australie] ; Hagop M. Kantarjian [États-Unis] ; Dong-Wook Kim [Corée du Sud] ; Richard A. Larson [États-Unis] ; Jeffrey H. Lipton [Canada] ; François-Xavier Mahon [France] ; Giovanni Martinelli [Italie] ; Jiri Mayer [République tchèque] ; Martin C. Müller [Allemagne] ; Dietger Niederwieser [Allemagne] ; Fabrizio Pane [Italie] ; Jerald P. Radich [États-Unis] ; Philippe Rousselot [France] ; Giuseppe Saglio [Italie] ; Susanne Sau Ele [Allemagne] ; Charles Schiffer [États-Unis] ; Richard Silver [États-Unis] ; Bengt Simonsson [Suède] ; Juan-Luis Steegmann [Espagne] ; John M. Goldman [Royaume-Uni] ; Rüdiger Hehlmann [Allemagne] | European LeukemiaNet recommendations for the management of chronic myeloid leukemia: 2013 |
| 001470 (2013) |
Hagop M. Kantarjian [États-Unis] ; Giovanni Martinelli [Italie] ; Elias J. Jabbour [États-Unis] ; Alfonso Ouintas-Cardama [États-Unis] ; Kiyoshi Ando [Japon] ; Jacques-Olivier Bay [France] ; Andrew Wei [Australie] ; Stefanie Gröpper [Allemagne] ; Cristina Papayannidis [Italie] ; Kate Owen [Royaume-Uni] ; Laura Pike [Royaume-Uni] ; Nicola Schmitt [Royaume-Uni] ; Paul K. Stockman [Royaume-Uni] ; Aristoteles Giagounidis [Allemagne] | Stage I of a Phase 2 Study Assessing the Efficacy, Safety, and Tolerability of Barasertib (AZD1152) Versus Low-Dose Cytosine Arabinoside in Elderly Patients With Acute Myeloid Leukemia |
| 002200 (2008) |
Philipp Le Coutre [Allemagne] ; Oliver G. Ottmann [Allemagne] ; Francis Giles [États-Unis] ; Dong-Wook Kim [Corée du Sud] ; Jorge Cortes [États-Unis] ; Norbert Gattermann [Allemagne] ; Jane F. Apperley [Royaume-Uni] ; Richard A. Larson [États-Unis] ; Elisabetta Abruzzese [Italie] ; Stephen G. O'Brien [Royaume-Uni] ; Kazimierz Kuliczkowski [Pologne] ; Andreas Hochhaus [Allemagne] ; Francois-Xavier Mahon [France] ; Giuseppe Saglio [Italie] ; Marco Gobbi [Italie] ; Yok-Lam Kwong [Hong Kong] ; Michele Baccarani [Italie] ; Timothy Hughes [Australie] ; Giovanni Martinelli [Italie] ; Jerald P. Radich [États-Unis] ; MING ZHENG [États-Unis] ; YAPING SHOU [États-Unis] ; Hagop Kantarjian [États-Unis] | Nilotinib (formerly AMN107), a highly selective BCR-ABL tyrosine kinase inhibitor, is active in patients with imatinib-resistant or -intolerant accelerated-phase chronic myelogenous leukemia |
| 002541 (2006) |
Timothy Hughes [Australie, États-Unis, Allemagne, Royaume-Uni, Italie, France, Canada] ; Michael Deininger ; Andreas Hochhaus ; Susan Branford ; Jerald Radich ; Jaspal Kaeda ; Michele Baccarani ; Jorge Cortes ; Nicholas C. P. Cross ; Brian J. Druker ; Jean Gabert ; David Grimwade ; Rüdiger Hehlmann ; Suzanne Kamel-Reid ; Jeffrey H. Lipton ; Janina Longtine ; Giovanni Martinelli ; Giuseppe Saglio ; Simona Soverini ; Wendy Stock ; John M. Goldman | Monitoring CML patients responding to treatment with tyrosine kinase inhibitors : review and recommendations for harmonizing current methodology for detecting BCR-ABL transcripts and kinase domain mutations and for expressing results |
List of associated KwdEn.i
Nombre de
documents | Descripteur |
|---|
| 2 | Antineoplastic agent |
| 2 | Human |
| 2 | Humans |
| 2 | Hybrid gene |
| 2 | Philadelphia chromosome |
| 2 | Prognosis |
| 2 | Protein-tyrosine kinase |
| 1 | Abnormal chromosome C9 |
| 1 | Abnormal chromosome G22 |
| 1 | Acute myelogenous leukemia |
| 1 | Aged |
| 1 | Aged, 80 and over |
| 1 | Antimetabolites, Antineoplastic (therapeutic use) |
| 1 | Antineoplastic Combined Chemotherapy Protocols (therapeutic use) |
| 1 | Antiviral |
| 1 | Azacitidine (therapeutic use) |
| 1 | Barasertib |
| 1 | Blast Crisis (drug therapy) |
| 1 | Blast Crisis (pathology) |
| 1 | C-Onc gene |
| 1 | Cancerology |
| 1 | Chromosome translocation |
| 1 | Chronic |
| 1 | Chronic myelocytic leukemia |
| 1 | Chronic myelogenous leukemia |
| 1 | Comparative study |
| 1 | Cytarabine |
| 1 | DNA Mutational Analysis (methods) |
| 1 | DNA Mutational Analysis (trends) |
| 1 | Drug Resistance, Neoplasm (genetics) |
| 1 | Early stage |
| 1 | Elderly |
| 1 | Enzyme inhibitor |
| 1 | Female |
| 1 | Follow-Up Studies |
| 1 | Forecasting |
| 1 | Fusion Proteins, bcr-abl (genetics) |
| 1 | Fusion protein |
| 1 | Gene expression |
| 1 | Hematology |
| 1 | Imatinib |
| 1 | International Agencies |
| 1 | Leukemia, Myelogenous, Chronic, BCR-ABL Positive (drug therapy) |
| 1 | Leukemia, Myelogenous, Chronic, BCR-ABL Positive (genetics) |
| 1 | Leukemia, Myeloid, Acute (drug therapy) |
| 1 | Leukemia, Myeloid, Acute (mortality) |
| 1 | Leukemia, Myeloid, Acute (pathology) |
| 1 | Low dose |
| 1 | Male |
| 1 | Minimal residual disease |
| 1 | Mutation |
| 1 | Neoplasm Staging |
| 1 | Nilotinib |
| 1 | Non-specific serine/threonine protein kinase |
| 1 | Phase I trial |
| 1 | Polymerase chain reaction |
| 1 | Practice Guidelines as Topic |
| 1 | Prospective Studies |
| 1 | Protein Kinase Inhibitors (pharmacology) |
| 1 | Protein Kinase Inhibitors (therapeutic use) |
| 1 | Protein inhibitor |
| 1 | Real time |
| 1 | Resistance |
| 1 | Review |
| 1 | Surveillance |
| 1 | Survival Rate |
| 1 | Toxicity |
| 1 | Treatment |
| 1 | Treatment efficiency |
| 1 | Tyrosine kinase inhibitor |
Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Wicri/Asie/explor/AustralieFrV1/Data/Allemagne/Analysis
HfdIndexSelect -h $EXPLOR_AREA/Data/Allemagne/Analysis/Author.i -k "Giovanni Martinelli"
HfdIndexSelect -h $EXPLOR_AREA/Data/Allemagne/Analysis/Author.i \
-Sk "Giovanni Martinelli" \
| HfdSelect -Kh $EXPLOR_AREA/Data/Allemagne/Analysis/biblio.hfd
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= Wicri/Asie
|area= AustralieFrV1
|flux= Allemagne
|étape= Analysis
|type= indexItem
|index= Author.i
|clé= Giovanni Martinelli
}}
| This area was generated with Dilib version V0.6.33.
Data generation: Tue Dec 5 10:43:12 2017. Site generation: Tue Mar 5 14:07:20 2024 |  |
